Balyasny Asset Management
NUVB icon

Balyasny Asset Management’s Nuvation Bio NUVB Stock Holding History

Balyasny Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
217,124
+154,603
+247% +$756K ﹤0.01% 2096
2026
Q1 		$268K Buy
+62,521
New +$348K ﹤0.01% 2604
2025
Q4 		– Sell
-62,472
Closed -$231K – 3413
2025
Q3 		$231K Sell
62,472
-69,824
-53% -$190K ﹤0.01% 2677
2025
Q2 		$258K Buy
+132,296
New +$276K ﹤0.01% 2522
2024
Q4 		– Sell
-95,725
Closed -$219K – 3110
2024
Q3 		$219K Buy
+95,725
New +$292K ﹤0.01% 2536
2023
Q1 		– Sell
-44,098
Closed -$84.7K – 2998
2022
Q4 		$84.7K Buy
+44,098
New +$89.2K ﹤0.01% 2270
2021
Q2 		– Sell
-21,642
Closed -$226K – 2232
2021
Q1 		$226K Buy
+21,642
New +$242K ﹤0.01% 1561

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Balyasny Asset Management's NUVB Position: Q2 2026 in Review

Balyasny Asset Management increased its Nuvation Bio (NUVB) stake by 247% in Q2 2026, buying an estimated $756K and bringing the position to 217,124 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2096.

Balyasny Asset Management first reported a position in NUVB in Q1 2021 and has held it in 7 quarters since. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Balyasny Asset Management held 217,124 shares of Nuvation Bio worth $1.23M as of Q2 2026.
  • Balyasny Asset Management bought 154,603 Nuvation Bio shares in Q2 2026, an estimated $756K.
  • Nuvation Bio made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2096 holding.
  • Balyasny Asset Management first reported a position in Nuvation Bio in Q1 2021 and has held it in 7 quarters since.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.